Results 191 to 200 of about 141,694 (266)

Hepatitis B surface antigen hijacks TANK-binding kinase 1 to suppress type I interferon and induce early autophagy. [PDF]

open access: yesCell Death Dis
Luo C   +11 more
europepmc   +1 more source

Beyond Starch: Towards a Scalable Potato Platform for Molecular Farming

open access: yesPlant Biotechnology Journal, Volume 24, Issue 7, Page 4619-4639, July 2026.
Re‐engineering potato as a biosafe and host‐optimised platform for plant molecular farming by integrating intrinsic biological traits with targeted engineering strategies. ABSTRACT Thirty‐five years after the first recombinant protein was produced in potato and 30 years after clinical trials of edible vaccines from its tubers, the crop is being ...
Izabela Anna Chincinska   +2 more
wiley   +1 more source

Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens. [PDF]

open access: yesWorld J Gastroenterol
Lu R   +15 more
europepmc   +1 more source

Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3268-3278, 15 June 2026.
What's new? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt   +6 more
wiley   +1 more source

Viral sequence determines HLA-E-restricted T cell recognition of hepatitis B surface antigen. [PDF]

open access: yesNat Commun
Murugesan G   +31 more
europepmc   +1 more source

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3252-3267, 15 June 2026.
What's new? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott   +10 more
wiley   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, Volume 20, Issue 6, Page 1453-1472, June 2026.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

Impact of Hepatitis Delta Virus Infection on the Selection of Hepatitis B Surface Antigen Mutations. [PDF]

open access: yesGenes (Basel)
Baruti K   +11 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, Volume 20, Issue 6, Page 1591-1611, June 2026.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy